

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
19 October 2000 (19.10.2000)

PCT

(10) International Publication Number
WO 00/61138 A1(51) International Patent Classification⁷: A61K 31/255.
31/35, 31/7048, A61P 25/00, 25/28

(21) International Application Number: PCT/US00/08401

(22) International Filing Date: 30 March 2000 (30.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/128,297 8 April 1999 (08.04.1999) US
09/538,815 30 March 2000 (30.03.2000) US(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(48) Date of publication of this corrected version:

10 January 2002

(15) Information about Correction:

see PCT Gazette No. 02/2002 of 10 January 2002, Section II



(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).

(72) Inventors: SHANK, Richard, P.; 551 Village Circle, Blue Bell, NJ 19422-1636 (US). SMITH-SWINTOSKY, Ginger; 3163 Line Lexington Road, Hatfield, PA 19440 (US). ZHAO, Boyu; 105 Weymouth Circle, Lansdale, PA 19446 (US).

(74) Agents: CIAMPORCERO, Audley, A., Jr. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTICONVULSANT DERIVATIVES USEFUL IN TREATING CHRONIC NEURODEGENERATIVE DISORDERS



(57) Abstract: Use of anticonvulsant derivatives of formula (I) for treating chronic neurodegenerative conditions, wherein X is CH₂ or oxygen; R₁ is hydrogen or C₁-C₁ alkyl; and R₂, R₃, R₄ and R₅ are independently hydrogen or alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of formula (II), wherein R₆ and R₇ are the same or different and are hydrogen, or alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

WO 00/61138 A1

best Available Copy



This Page Blank (user)



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: A61K 31/255, 31/35, 31/7048, A61P 25/00, 25/28		A1	(11) International Publication Number: WO 00/61138
			(43) International Publication Date: 19 October 2000 (19.10.00)
(21) International Application Number: PCT/US00/08401		(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 30 March 2000 (30.03.00)		<p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
(30) Priority Data: 60/128,297 8 April 1999 (08.04.99) US Not furnished 30 March 2000 (30.03.00) US			
(71) Applicant: ORTHO-MCNEIL PHARMACEUTICAL, INC. [US/US]; U.S. Route #202, P.O. Box 300, Raritan, NJ 08869-0602 (US).			
(72) Inventor: SHANK, Richard, P.; 551 Village Circle, Blue Bell, NJ 19422-1636 (US).			
(74) Agents: CIAMPORCERO, Audley, A., Jr. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, NJ 08933 (US).			

(54) Title: ANTICONVULSANT DERIVATIVES USEFUL IN TREATING CHRONIC NEURODEGENERATIVE DISORDERS



(57) Abstract

Use of anticonvulsant derivatives of formula (I) for treating chronic neurodegenerative conditions, wherein X is CH₂ or oxygen; R₁ is hydrogen or C₁-C₄ alkyl; and R₂, R₃, R₄ and R₅ are independently hydrogen or alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of formula (II), wherein R₆ and R₇ are the same or different and are hydrogen, or alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ANTICONSULSANT DERIVATIVES USEFUL IN TREATING CHRONIC NEURODEGENERATIVE DISORDERS

BACKGROUND OF THE INVENTION

Compounds of Formula I:



are structurally novel antiepileptic compounds that are highly effective anticonvulsants in animal tests (Maryanoff, B.E., Northey, S.O., Gardocki, J.F., Shank, R.P. and Dodgson, S.P. *J. Med. Chem.* **30**, 880-887, 1987; Maryanoff, B.E., Costanzo, M.J., Shank, R.P., Schupsky, J.J., Ortegon, M.E., and Vaught J.L. *Bioorganic & Medicinal Chemistry Letters* **3**, 2653-2656, 1993). These compounds are covered by three US Patents: No.4,513,006, No.5,242,942, and No.5,384,327. One of these compounds 2,3:4,5-bis-O-(1-methylethylidene)- β -D-fructopyranose sulfamate known as topiramate has been demonstrated in clinical trials of human epilepsy to be effective as adjunctive therapy or as monotherapy in treating simple and complex partial seizures and secondarily generalized seizures (E. FAUGHT, B.J. WILDER, R.E. RAMSEY, R.A. REIFE, L D. KRAMER, G.W. PLEDGER, R.M. KARIM et. al., *Epilepsia* **36 (S4)** 33, 1995; S.K. SACHDEO, R.C. SACHDEO, R.A. REIFE, P. LIM and G. PLEDGER, *Epilepsia* **36 (S4)** 33, 1995), and is currently marketed for the treatment of simple and complex partial seizure epilepsy with or without secondary generalized seizures in approximately twenty countries including the United States, and applications for regulatory approval are presently pending in several additional countries throughout the world.


Compounds of Formula I were initially found to possess anticonvulsant activity in the traditional maximal electroshock seizure (MES) test in mice (SHANK, R.P., GARDOCKI, J.F., VAUGHT, J.L., DAVIS, C.B., SCHUPSKY, J.J., RAFFA, R.B., DODGSON, S.J., NORTEY, S.O., and MARYANOFF, B.E., *Epilepsia* **35** 450-460, 1994). Subsequent studies revealed that Compounds of Formula I were also highly effective in the MES test in rats. More recently topiramate was found to effectively block seizures in several rodent models of epilepsy (J. NAKAMURA, S. TAMURA, T.

KANDA, A. ISHII, K. ISHIHARA, T. SERIKAWA, J. YAMADA, and M. SASA, Eur. J. Pharmacol. 254 83-89, 1994), and in an animal model of kindled epilepsy (A. WAUQUIER and S. ZHOU, Epilepsy Res. 24 73-77, 1996).

Recent preclinical studies on topiramate have revealed previously unrecognized pharmacological properties which suggest that topiramate should be effective in treating some other neurological disorders. One of these is chronic neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, diabetic neuropathies, retinopathy, peripheral nerve injury and brain and spinal neurodegeneration arising as a result of head trauma or spinal injury.

DISCLOSURE OF THE INVENTION


Accordingly, it has been found that compounds of the following formula I:



wherein X is O or CH₂, and R₁, R₂, R₃, R₄ and R₅ are as defined hereinafter are useful in treating chronic neurodegenerative conditions, such as occurs in Alzheimer's disease, Parkinson's disease, Huntington's disease, multiple sclerosis, diabetic neuropathies, retinopathy, peripheral nerve injury and brain and spinal neurodegeneration arising as a result of head trauma or spinal injury.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The sulfamates of the invention are of the following formula (I):




wherein

X is CH₂ or oxygen;

R₁ is hydrogen or alkyl; and

R₂, R₃, R₄ and R₅ are independently hydrogen or alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the following formula (II):



wherein


R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

R₁ in particular is hydrogen or alkyl of about 1 to 4 carbons, such as methyl, ethyl and iso-propyl. Alkyl throughout this specification includes straight and branched chain alkyl. Alkyl groups for R₂, R₃, R₄, R₅, R₆ and R₇ are of about 1 to 3 carbons and include methyl, ethyl, iso-propyl and n-propyl. When X is CH₂, R₄ and R₅ may combine to form a benzene ring fused to the 6-membered X-containing ring, i.e., R₄ and R₅ are defined by the alkatrienyl group =C-CH=CH-CH=.

A particular group of compounds of formula (I) is that wherein X is oxygen and both R₂ and R₃ and R₄ and R₅ together are methylenedioxy groups of the formula (II), wherein R₆ and R₇ are both hydrogen both alkyl or combine to form a spiro cyclopentyl or cyclohexyl ring, in particular where R₆ and R₇ are both alkyl such as methyl. A second group of compounds is that wherein X is CH₂ and R₄ and R₅ are joined to form a benzene ring. A third group of compounds of formula (I) is that wherein both R₂ and R₃ are hydrogen.

The compounds of formula (I) may be synthesized by the following methods:

(a) Reaction of an alcohol of the formula RCH₂OH with a chlorosulfamate of the formula ClSO₂NH₂ or ClSO₂NHR₁ in the presence of a base such as potassium α-butoxide or sodium hydride at a temperature of about -20° to 25° C and in a solvent such as toluene, THF or dimethylformamide wherein R is a moiety of the following formula (III):



(b) Reaction of an alcohol of the formula RCH_2OH with sulfurylchloride of the formula SO_2Cl_2 in the presence of a base such as triethylamine or pyridine at a temperature of about -40° to 25° C in a solvent such as diethyl ether or methylene chloride to produce a chlorosulfate of the formula RCH_2OSO_2Cl .

The chlorosulfate of the formula RCH_2OSO_2Cl may then be reacted with an amine of the formula R_1NH_2 at a temperature of about 40° to 25° C in a solvent such as methylene chloride or acetonitrile to produce a compound of formula (I). The reaction conditions for (b) are also described by T. Tsuchiya et al. in Tet. Letters, No. 36, p. 3365 to 3368 (1978).

(c) Reaction of the chlorosulfate RCH_2OSO_2Cl with a metal azide such as sodium azide in a solvent such as methylene chloride or acetonitrile yields an azidosulfate of the formula $RCH_2OSO_2N_3$ as described by M. Hedayatullah in Tet. Lett. p. 2455-2458 (1975). The azidosulfate is then reduced to a compound of formula (I) wherein R_1 is hydrogen by catalytic hydrogenation, e.g. with a noble metal and H_2 or by heating with copper metal in a solvent such as methanol.

The starting materials of the formula RCH_2OH may be obtained commercially or as known in the art. For example, starting materials of the formula RCH_2OH wherein both R_2 and R_3 and R_4 and R_5 are identical and are of the formula (II) may be obtained by the method of R. F. Brady in Carbohydrate Research, Vol. 14, p. 35 to 40 (1970) or by reaction of the trimethylsilyl enol ether of a R_6COR_7 ketone or aldehyde with fructose at a temperature of about 25° C, in a solvent such a halocarbon, e.g. methylene chloride in the presence of a protic acid such as hydrochloric acid or a Lewis Acid such as zinc chloride. The trimethylsilyl enol ether reaction is described by G. L. Larson et al in J. Org. Chem. Volaa 38, No. 22, p. 3935 (1973).

Further, carboxylic acids and aldehydes of the formulae $RCOOH$ and $RCHO$ may be reduced to compounds of the formula RCH_2OH by standard reduction techniques, e.g. reaction with lithium aluminum hydride, sodium borohydride or borane-THF complex in an inert solvent such a diglyme, THF or toluene at a

temperature of about 100° C, e.g. as described by H.O. House in "Modern Synthetic Reactions", 2nd Ed., pages 45 to 144 (1972).


The compounds of formula I: may also be made by the process disclosed in US Patents: No.4,513,006, No.5,242,942, and No.5,384,327, which are incorporated by reference herein.

The compounds of formula I include the various individual isomers as well as the racemates thereof, e.g., the various alpha and beta attachments, i.e., below and above the plane of the drawing, of R₂, R₃, R₄ and R₅ on the 6-membered ring. Preferably, the oxygens of the methylenedioxy group (II) are attached on the same side of the 6-membered ring.

The ability of the compounds of formula I to treat chronic neurodegenerative disorders is based from the results of studies in which topiramate was found to promote neurite outgrowth in neuronal cells in culture and to enhance nerve regeneration and recovery of function after injury in vivo


In studies in vitro, cultures of rat hippocampal and cerebral cortical cells were established from embryonic day 18 pups. The cells were grown in culture wells (plates) for seven days in the presence of various concentrations of topiramate (0.1nM-100uM), or the neurotrophic factors BDNF (brain-derived neurotrophic, 10ng) and α -MSH (alpha-melanocyte stimulating hormone, 50nM), or vehicle (isotonic saline). Each compound was added to the culture medium in a specified set of wells at the time the cells were plated and then again four days later when the culture media was removed and replaced with fresh media. On the seventh day in culture, the cells were treated with formalin, a tissue fixative. Subsequently, the cells were treated with a fluorescein-labeled antibody specific for microtubule associated protein-2 (MAP-2), a selective marker for dendritic processes. The amount of fluorescein-labeled antibody bound to MAP-2 (FITC signal) in each well was analytically determined. This information was then used to calculate the relative degree of neurite outgrowth for the cells in each well. When compared to cells grown in medium containing only vehicle, the topiramate-treated cells exhibited a significantly higher level of FITC signal, thereby indicating that topiramate induced an increase in neurite outgrowth. For hippocampal cells, the increase was significantly higher ($P < 0.05$) at concentrations ranging from 100nM to 100 μ M (Fig. 1). However, a clear concentration-response effect was not observed.

**Figure 1. Topiramate Dose Response
Rat Hippocampus (7dic)
Neurite Outgrowth - MAP2-FITC Assay**



For cortical cells a significant increase was observed at 100nM (119% of control) and 10μM (119% of control) ($p < 0.05$). No dose-response relationship was evident, but topiramate treatment resulted in a modest increase in neurite outgrowth at most concentrations studied (range=106% to 119% of control).


**Figure 2. Topiramate Dose Response
Rat Cerebral Cortex (7dic)
Neurite Outgrowth - MAP2-FITC Assay**



In the study in vivo, topiramate was evaluated in a rat facial nerve compression model of peripheral nerve injury. Rats were anesthetized, their skin and muscle excised to visualize the facial nerve. The nerve was injured near the stylom by compression with forceps. The wound was sutured and the rat allowed to recover before compound administration. The rats were divided into three groups: vehicle-treated, topiramate-treated (p.o., 20mg/kg) and α-MSH-treated (s.c., 1mg/kg). Compounds were administered twice daily for 14 days post-surgery. Facial nerve compression causes

paralysis of the whisker muscle ipsilateral to the injury site. Restoration of whisker movement (lesioned versus non-lesioned side) was monitored daily for 14 days. Spontaneous recovery of whisker movement was detected as early as 10 days post-surgery with full recovery achieved by 13 days. On days 11 and 12 the degree of whisker movement recovery was significantly higher for the topiramate-treated group of rats than for the vehicle-treated group (day 11 % recovery; topiramate = 60%, vehicle = 19%; $p < 0.001$) (day 12 recovery; topiramate = 92%, vehicle = 68%, $p < 0.01$). By comparison, the α -MSH treated group exhibited a smaller, statistically nonsignificant increase in recovery at days 11 and 12 (Figure 3).

Figure 3. Recovery Rate After Oral Administration of Topiramate and α -MSH in the Facial Nerve Compression Model




For treating chronic neurodegenerative conditions, topiramate or another compound of formula (I) may be employed by administering repeated oral doses in the range of about 16 to 256 mg once or twice daily.

To prepare the pharmaceutical compositions of this invention, one or more sulfamate compounds of formula (I) are intimately admixed with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques, which carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., i.v.. Sterile injectable formulations will be prepared using appropriate solubilizing agents. A unit dose would contain about 10 to 100 mg of the

active ingredient [REDACTED] piramate is currently available for oral administration in round tablets containing 25 mg, 100 mg or 200 mg of active agent. The tablets contain the following inactive ingredients: lactose hydrous, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hydroxypropyl methylcellulose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.

WHAT IS CLAIMED IS:

1. A method for treating chronic neurodegeneration comprising administering to a mammal afflicted with such condition a therapeutically effective amount of a compound




of the formula I:

wherein

X is CH₂ or oxygen;

R₁ is hydrogen or alkyl; and

R₂, R₃, R₄ and R₅ are independently hydrogen or alkyl and, when X is CH₂, R₄ and R₅ may be alkene groups joined to form a benzene ring and, when X is oxygen, R₂ and R₃ and/or R₄ and R₅ together may be a methylenedioxy group of the following formula (II):



wherein

R₆ and R₇ are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.

2. The method of claim 1 wherein the compound of formula I is topiramate.
3. The method of claim 1, wherein the expected therapeutically effective amount is from about 32 to 512 mg.
4. The method of claim 1, wherein the dose amount for oral administration is of from about 16 to 256 mg.

INTERNATIONAL SEARCH REPORT

Int'l Application No

PCT/US 00/08401

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/255 A61K31/35 A61K31/7048 A61P25/00 A61P25/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, MEDLINE, BIOSIS, EMBASE, SCISEARCH

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO 00 01376 A (SMITH TERENCE ;TURSKI LECHOSLAW (GB); EISAI CO LTD (JP)) 13 January 2000 (2000-01-13) abstract page 1, line 1 -page 4, line 25; claims 1-7,9	1-4
X	WO 98 00131 A (ORTHO PHARMA CORP) 8 January 1998 (1998-01-08) the whole document --- -/--	1-4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

8 August 2000

Date of mailing of the international search report

22/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, fax 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Hoff, P

INTERNATIONAL SEARCH REPORT

Int lional Application No

PCT/US 00/08401

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ANGEHAGEN, MIKAEL ET AL: "Does topiramate (TPM) have protective effects on astroglia cells and neurons in primary cortical cultures." EPILEPSIA, (1998) VOL. 39, NO. SUPPL. 6, PP. 44. MEETING INFO.: ANNUAL MEETING OF THE AMERICAN EPILEPSY SOCIETY SAN DIEGO, CALIFORNIA, USA DECEMBER 6-9, 1998 , XP000923162 abstract 2.050 ---	1-4
A	B. MELDRUM ET AL.: "Excitatory amino acid neurotoxicity and neurodegenerative disease" TIPS, vol. 11, 1990, pages 379-387, XP000915223 the whole document ---	1-4
A	US 5 731 348 A (GU ZI-QIANG) 24 March 1998 (1998-03-24) abstract column 17, line 60 -column 20, line 12 ---	1-4
A	WO 98 00124 A (ORTHO PHARMA CORP) 8 January 1998 (1998-01-08) the whole document ---	1-4
A	Y. YANG ET AL.: "Neuroprotection by delayed administration of topiramate in a rat model of middle cerebral artery embolization" BRAIN RESEARCH, vol. 804, no. 2, 1998, pages 169-176, XP000921218 the whole document ---	1-4
A	WO 98 00123 A (ORTHO PHARMA CORP) 8 January 1998 (1998-01-08) the whole document -----	1-4

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/08401

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0001376	A	13-01-2000	NONE	
WO 9800131	A	08-01-1998	AU 3501097 A	21-01-1998
			CA 2258892 A	08-01-1998
			CZ 9804279 A	11-08-1999
			EP 0936908 A	25-08-1999
			NO 986054 A	01-03-1999
			US 5753694 A	19-05-1998
			ZA 9705764 A	28-12-1998
US 5731348	A	24-03-1998	CA 2216648 A	22-08-1996
			EP 0809624 A	03-12-1997
			JP 11501619 T	09-02-1999
			WO 9625387 A	22-08-1996
WO 9800124	A	08-01-1998	AU 3501697 A	21-01-1998
			ZA 9705769 A	28-12-1998
WO 9800123	A	08-01-1998	AU 3219797 A	05-01-1998
			AU 3409697 A	21-01-1998
			CA 2258895 A	08-01-1998
			CZ 9804277 A	11-08-1999
			NO 986051 A	23-02-1999
			US 5977964 A	02-11-1999
			WO 9747135 A	11-12-1997
			US 5945988 A	31-08-1999

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☒ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☒ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

This Page Blank (uspto)